-
Lisata Therapeutics reports preliminary pancreatic cancer trial results
-
H.C. Wainwright Reiterates Buy Rating on Lisata Therapeutics, Inc (LSTA)
-
Caladrius Biosciences, Inc. (LSTA) Tops Q2 EPS by 10c
-
Lisata Therapeutics, Inc (LSTA) PT Raised to $32 at Brookline Capital Markets
-
Lisata Therapeutics receives new patent for certepetide through 2040
-
H.C. Wainwright Reiterates Buy Rating on Lisata Therapeutics, Inc (LSTA)
-
Caladrius Biosciences, Inc. (LSTA) Tops Q1 EPS by 19c
-
Lisata Therapeutics (LSTA) Announces Research License with Catalent
-
Lisata Therapeutics (LSTA) and GATC Health Consummate First Step in Strategic Collaboration to use AI to Derisk and Accelerate Drug Development
-
Lisata Therapeutics (LSTA) and WARPNINE Announce Encouraging Preliminary Results from the Phase 1b/2a iLSTA Trial Evaluating Certepetide in Locally Advanced Non-Resectable Pancreatic Ductal Adenocarci
-
First Berlin Research Starts Lisata Therapeutics, Inc (LSTA) at Buy, 'We see 2025 as an exciting year for Lisata as we also expect results on the other ongoing trials of certepetide'
-
Lisata Therapeutics (LSTA) and Kuva Labs Announce Global License Agreement for Solid Tumor Imaging
-
Caladrius Biosciences, Inc. (LSTA) Tops Q3 EPS by 16c
-
Lisata Therapeutics (LSTA) and Valo Therapeutics Announce Preclinical Research Collaboration
-
H.C. Wainwright Reiterates Buy Rating on Lisata Therapeutics, Inc (LSTA)
-
Lisata Therapeutics' (LSTA) Certepetide Granted FDA Orphan Drug Designation for the Treatment of Cholangiocarcinoma
-
H.C. Wainwright Reiterates Buy Rating on Lisata Therapeutics, Inc (LSTA)
-
Caladrius Biosciences, Inc. (LSTA) Tops Q2 EPS by 14c
-
H.C. Wainwright Reiterates Buy Rating on Lisata Therapeutics, Inc (LSTA)
-
Lisata Therapeutics's (LSTA) Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in a Preclinical Model

